key: cord-0854171-fm6ubsph
authors: Lodato, Francesca; Larocca, Anna; D’Errico, Antonietta; Cennamo, Vincenzo
title: AN ANUSUAL CASE OF ACUTE CHOLESTATIC HEPATITIS AFTER m-RNABNT162b2 (COMIRNATY) SARS-CoV-2 VACCINE: COINCIDENCE, AUTOIMMUNITY OR DRUG RELATED LIVER INJURY?
date: 2021-07-10
journal: J Hepatol
DOI: 10.1016/j.jhep.2021.07.005
sha: 7a5b953382f05903c58e61bb0e05ac0e80812d92
doc_id: 854171
cord_uid: fm6ubsph

nan

We read with interest the article "Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?" by Bril F. et al, recently published in J Hepatol. [1] This case autoimmune hepatitis had some atypical features as the absence of immunoglobulin G elevation and the presence of eosinophil at liver histology.

We recently observed a case of severe cholestatic hepatitis occurred after the administration of m-RNA-BNT162b1 (Comirnaty©, Pfeizer Biontech), with no development of autoantibodies and with the presence of eosinophil infiltrate at liver histology, who dramatically responded to steroid treatment, similarly to autoimmune hepatitis.

The patient, 43 years old women, presented to the hospital on February the 4 th , for jaundice and itching. At admission total bilirubin was 17.54 mg/dl (direct bilirubin 12.94), ALT 52 U/L, AST 51 U/L. Personal history was negative, except a mild dyslipidaemia with intermittent ALT increase, treated with diet (ALT and cholesterol maximum level 50 U/L and 285 mg/dl respectively). Because of legs venous insufficiency, she took ginkgo-biloba in August 2020, withdrawn next October, more than 100 days before admission. She was a sanitary assistant therefore she received Comirnaty vaccine (first dose January the 12 th , second February the 2 nd ). Itching started on January 27 th and by February the 4 th , she noticed jaundice. No other adverse events related to vaccine were reported.

Abdominal examination was negative; she had mild abdominal pain in right hypochondrium.

Ultrasonography, CTscan and CholangioMRI showed normal liver and biliary system. Seromarkers ruled out hepatitis A, B, C, and E; CMV, EBV and HIV. HCV-RNA and HBV-DNA tested also negative. Autoimmune study was negative (anti-nuclear antibodies, anti-smooth muscle, anti-liver/kidney microsomal type-1, antimitochondrial, anti-extractable nuclear antigens). Finally, gamma-globulins (including subclasses), coagulation, ceruloplasmin, blood count, platelets, iron status, IL-6 and thyroid function were normal. Serum albumin was slightly low (2.8 g/dl) and molecular test on rhino-pharyngeal swab for Sars-COV19 tested J o u r n a l P r e -p r o o f negative repeatedly while antibodies for Sars-COV2 showed effective immunological response to vaccination (SARS Cov-2 S1-S2 IgG 179 UA/mL).

Liver biopsy showed moderate portal inflammatory infiltrate and interface hepatitis in the portal tract with biliary injury and mild ductular proliferation; in the lobule spotty necrosis, lymphocytes along the sinusoid, focal moderate steatosis and intranuclear glycogen inclusions. No sinusoidal dilatation or fibrosis.

Immunostain with cH7-Ab, showed mild ductular proliferation and diffuse immunoreaciticy in hepatocytes zone 1-2 ( Fig.1) N-Acetyl-Cystein (9 gr ev for 3 days) was administered at day 3 from admission. Nevertheless, bilirubin raised up to 29.15 mg/dl (direct bilirubin of 19.9 mg/dl) with ALT 171 U/L and AST 132 U/L on day 10. Therefore, steroids were started (metilprednisolone 1 mg/Kg/die) observing a slow decrease of liver function test until complete normalization in eight weeks' time.

The case was reported to Italian sanitary authority (AIFA, Agenzia Italiana del Farmaco) and patient was warned about re-exposure to the vaccine.

The new mRNA vaccines protect against infectious diseases by triggering immune response. In registration trials, no cases of hepatitis were recorded [2] . The association between vaccine and autoimmune manifestations has been reported in different settings [3] [4] [5] [6] . Our patient didn't develop autoantibodies, nor liver histology showed typical signs of autoimmune damage. Nevertheless, two factors suggest immune mediated hepatitis: the first is the timeline from vaccine to liver alteration which may correspond with the development of the immune response. The second, is the excellent response to steroids. Besides these hypotheses, the pathogenetic mechanism of this possible form of hepatitis is obviously to be clarified. Drugs can induce toxic hepatitis [7] , SARS-CoV-2 infection has been associated with the development of autoimmunity [3] and there are also cases of drug-induced hepatitis with features of autoimmunity [8] .

Similarly to the case reported by Bril F. et al [1] , eosinophils infiltrate was present at histology; this feature is more often observed in toxic or drug related liver injury but also in autoimmune hepatitis [7] . Our patient J o u r n a l P r e -p r o o f

Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Covid-19 and autoimmunity

Immune Thrombocytopenic Purpura in a Patient with Covid-19

Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19

Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination

European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Drug-induced liver injury

Drug-Induced Liver Injury Network. Features of Autoimmune Hepatitis in Patients With Drug-induced Liver Injury

Potential hepatic and renal toxicity induced by the biflavonoids from Ginkgo biloba